You are here

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

Last updated on April 12, 2018

FOR MORE INFORMATION
Study Location
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana, 46804 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Signed and dated informed consent form (by the patient or a legally acceptable
representative as per the local regulations) obtained prior to initiation of any
study-specific procedure and treatment.

2. Female or male of at least 18 years of age.

3. Histologically or cytologically confirmed advanced solid tumor with no available
standard approved treatment options in the opinion of the Investigator

4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.

5. Expected life expectancy of ≥ 3 months.

6. Able to swallow the study drug (no contra indication to oral agents).

7. Renal function at screening and enrollment as defined by the Modification of Diet in
Renal Disease (MDRD) equation.

8. Patient has had no clinically significant change in renal status within 3 months prior
to screening, according to Investigator's review of clinical patient records.

9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of
chronic kidney disease or acute failure/conditions.

10. Patient has no unstable renal function, defined as a change in estimated glomerular
filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with
mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe
renal impaired, from screening to enrollment.

11. Adequate other organ function at screening and enrollment.

12. Female patients of childbearing potential must have a negative serum pregnancy test at
screening, and must agree to use a highly effective birth control method from the time
of the first dose of study drug through 45 days after the last dose of study drug.

13. Male patients must agree to use a condom when having sex with a pregnant woman or with
a non-pregnant female partner of childbearing potential, from 21 days before the first
dose of study drug through 105 days after last dose of study drug.

14. Female patients must not be breastfeeding at screening nor during the study
participation until 45 days after the last dose of study drug.

15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
tests, and other trial procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Treatment within 14 days or five half lives prior to enrollment with any type of
systemic anticancer-therapy or any investigational drug, whichever is longer.

2. Have not recovered (recovery is defined as CTCAE grade ? 1) from the acute toxicities
of previous anticancer standard or investigational therapy, except treatment-related
alopecia or laboratory abnormalities otherwise meeting eligibility requirements.

3. Major surgery within 28 days prior to enrollment.

4. Serious accompanying cardiac disorder.

5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing
or requiring treatment.

6. Symptomatic or impending spinal cord compression or cauda equina syndrome.

7. Has undergone a liver transplant, kidney transplant or nephrectomy.

8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious
adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly
ADP ribose polymerase (PARP) inhibitor.

9. Known myelodysplastic syndrome.

10. Seropositive for human immunodeficiency virus (HIV).

11. Any serious or unstable medical condition that interferes with ability to tolerate
treatment or assessments associated with the protocol.

12. Gastrointestinal disorder affecting absorption.

13. Known or suspected hypersensitivity to any of the talazoparib capsule components.

14. Any condition or reason that interferes with ability to participate in the study,
tolerate treatment or assessments associated with the protocol, causes undue risk, or
complicates the interpretation of safety data, in the opinion of the Investigator or
Medical Monitor.

NCT02997163
Pfizer
Recruiting
An Open-Label Pharmacokinetics and Safety Study of Talazoparib

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Advanced/Metastatic Solid Tumors
NCT02444793
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors
NCT03070548
All Genders
18+
Years
Budapest,
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Advanced Breast Cancer, Metastatic Breast Cancer
NCT03280303
All Genders
18+
Years
Multiple Sites
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment
This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.
At the End of the Study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study after discussion with the Principal Investigator and obtaining Sponsor permission. Sponsor decision to allow the patient to continue dosing with talazoparib in an open-label extension study will be based on potential overall benefit-risk, patient acceptance and other relevant criteria.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Advanced Solid Tumors
Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg
Other Names:
  • MDV3800
  • BMN673
  • Experimental: Group A (control, normal renal function)
    Intervention: Drug: Talazoparib
  • Experimental: Group B (mild renal impairment)
    Intervention: Drug: Talazoparib
  • Experimental: Group C (moderate renal impairment)
    Intervention: Drug: Talazoparib
  • Experimental: Group D (severe renal impairment)
    Intervention: Drug: Talazoparib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
24
April 17, 2018
April 17, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.
  2. Female or male of at least 18 years of age.
  3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator
  4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ? 2.
  5. Expected life expectancy of ? 3 months.
  6. Able to swallow the study drug (no contra indication to oral agents).
  7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.
  8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.
  9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.
  10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.
  11. Adequate other organ function at screening and enrollment.
  12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.
  13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.
  14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.
  15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

  1. Treatment within 14 days or five half lives prior to enrollment with any type of systemic anticancer-therapy or any investigational drug, whichever is longer.
  2. Have not recovered (recovery is defined as CTCAE grade ? 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
  3. Major surgery within 28 days prior to enrollment.
  4. Serious accompanying cardiac disorder.
  5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing or requiring treatment.
  6. Symptomatic or impending spinal cord compression or cauda equina syndrome.
  7. Has undergone a liver transplant, kidney transplant or nephrectomy.
  8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.
  9. Known myelodysplastic syndrome.
  10. Seropositive for human immunodeficiency virus (HIV).
  11. Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.
  12. Gastrointestinal disorder affecting absorption.
  13. Known or suspected hypersensitivity to any of the talazoparib capsule components.
  14. Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Canada,   United States
 
 
NCT02997163
MDV3800-01
C3441001 ( Other Identifier: Alias Study Number )
2016-002536-33 ( EudraCT Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Medivation, Inc.
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now